After some discussion, my draft letter to the ASX was rewritten and sent this morning. I have blanked some parts of the letter and believe there is no justification for moderation.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%